Nexviazyme Injection, Powder, Lyophilized, For Solution
NDC Package 58468-0426-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Nexviazyme (avalglucosidase alfa-ngpt) injection is nEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Genzyme Corporation, this product is identified by NDC 58468-0426 and is authorized under FDA application BLA761194.

Identification & Billing

NDC Package Code
58468-0426-1
Package Description
1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE
Product Code
58468-0426
11-Digit Billing Format
58468042601
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Nexviazyme
Non-Proprietary Name
Avalglucosidase Alfa-ngpt
Substance Name
Avalglucosidase Alfa
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
AVALGLUCOSIDASE ALFA 100 mg/10mL
Pharmacologic Class
Usage Information
NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).

Regulatory & Marketing

Labeler Name
Genzyme Corporation
Product Type
Human Prescription Drug
FDA Application #
BLA761194
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
08-06-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J0219
Source: ASP
Inj aval alfa-nqpt 4mg
HCPCS Dosage 4 MG
Units / Pkg 25

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58468-0426-1 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 10 ml in 1 vial, single-dose of Nexviazyme, a human prescription drug labeled by Genzyme Corporation. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains avalglucosidase alfa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Genzyme Corporation on August 06, 2021. The current certification is valid through December 31, 2026.

How is this Genzyme Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58468042601. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
58468-0426-1
11-Digit CMS (5-4-2)
58468-0426-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.